Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N6-Benzyl adenosine‑5′‑diphosphate is a synthetic purine ribonucleotide analog in which the adenosine moiety is modified by a benzyl group at the N^6 position and contains a diphosphate group at the 5′ position. It is primarily used as a research tool in biochemical and molecular biology studies to probe enzyme mechanisms—especially those involving kinases or enzymes that recognize ADP or ATP analogs. This compound can act as an inhibitor of ATPase activities and has been used to study nucleotide binding sites and allosteric regulation of proteins. There are no known therapeutic indications; it is not approved for clinical use but is available for laboratory research purposes[1][2][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n6-benzyl adenosine-5'-diphosphate.